Cargando…

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves’ disease patients

Rapid iodine-131((131)I) turnover in the thyroid gland is an important feature of Graves’ disease (GD) and also a strong predictor of radioiodine therapy failure. The aim of this study was to explore the predictors of rapid (131)I turnover. The clinical data on 2543 patients were retrospectively rev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ruiguo, Tan, Jian, Wang, Renfei, Zhang, Guizhi, Jia, Qiang, Meng, Zhaowei, Zhang, Yueqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557855/ https://www.ncbi.nlm.nih.gov/pubmed/28811561 http://dx.doi.org/10.1038/s41598-017-08475-z

Ejemplares similares

Prediction of thyroidal (131)I effective half-life in patients with Graves' disease
por: Zhang, Ruiguo, et al.
Publicado: (2017)

Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy
por: Yu, Feng, et al.
Publicado: (2021)

Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer
por: Zhang, Ruiguo, et al.
Publicado: (2019)

Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study
por: Wang, Renfei, et al.
Publicado: (2017)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of (131)iodine treatment
por: Wang, Renfei, et al.
Publicado: (2017)

Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study
por: Chai, Jinyan, et al.
Publicado: (2022)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Effect of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2
por: Wang, Congcong, et al.
Publicado: (2020)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Paget disease in a radius
por: Zhang, Ruiguo, et al.
Publicado: (2018)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism
por: Doi, Suhail AR, et al.
Publicado: (2001)

Primary autoimmune thrombocytopenia and co-existing Graves’ disease: Role of radioiodine-131
por: Jung, Rayamajhi Sampanna, et al.
Publicado: (2014)

Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer
por: Upadhyaya, Arun, et al.
Publicado: (2017)

Retrospective study of the influence of hypothyroidism on liver function before radioiodine therapy in China: a comparison analysis based on patients with differentiated thyroid cancer
por: Ji, Yanhui, et al.
Publicado: (2022)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

A case report of (131)I therapy for Graves’ disease patient with hemiagenesis
por: Liu, Xuehui, et al.
Publicado: (2019)

Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer
por: Hu, Tianpeng, et al.
Publicado: (2016)

An improved method for the establishment of a model of Graves' disease in BALB/c mice
por: Zheng, Wei, et al.
Publicado: (2017)

Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
por: Gao, Haiyan, et al.
Publicado: (2023)

Radiosensitive effect of curcumin on thyroid cancer cell death induced by radioiodine-131
por: Hosseinimehr, Seyed Jalal, et al.
Publicado: (2014)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Nuclear Factor-Kappa B Inhibition Can Enhance Apoptosis of Differentiated Thyroid Cancer Cells Induced by (131)I
por: Meng, Zhaowei, et al.
Publicado: (2012)

Bone metastases in newly diagnosed patients with thyroid cancer: A large population-based cohort study
por: Zhang, Ruiguo, et al.
Publicado: (2022)

Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves’ disease
por: Zaman, Maseeh uz, et al.
Publicado: (2015)

Finding the best effective way of treatment for rapid I-131 turnover Graves’ disease patients: A randomized clinical trial
por: Thamcharoenvipas, Siwaporn, et al.
Publicado: (2019)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status
por: Liu, Na, et al.
Publicado: (2016)

Apoptosis gene reprograming of human peripheral blood mononuclear cells induced by radioiodine-131 ((131)I) irradiation
por: Li, Jian-Fang, et al.
Publicado: (2019)

The effect of radioiodine treatment on the characteristics of TRAb in Graves’ disease
por: Fang, Ya, et al.
Publicado: (2021)

Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy
por: Wang, Congcong, et al.
Publicado: (2022)

Time course of Graves’ orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer
por: Louvet, Camille, et al.
Publicado: (2016)

Effect of (131)I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer
por: Rui, Zhongying, et al.
Publicado: (2021)

HSA-MnO(2)-(131)I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma
por: Yan, Ziyu, et al.
Publicado: (2022)

Post-radioiodine management of patients with Graves' disease
por: Collins, K, et al.
Publicado: (2012)

Radioiodine therapy and Graves’ disease – Myths and reality
por: Plazinska, Maria Teresa, et al.
Publicado: (2020)

Radioiodine Therapy of Graves' Disease and the Uptake Paradox
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Gender impact on the correlation between thyroid function and serum lipids in patients with differentiated thyroid cancer
por: Li, Xue, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8ft48l5hv67uavobe2reg9e923